Keros Therapeutics Inc
NASDAQ:KROS
Net Margin
Keros Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Keros Therapeutics Inc
NASDAQ:KROS
|
548m USD |
2%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
329.9B USD |
7%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
150.1B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
134B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.9B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
114.1B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
56.4B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.5B USD |
-11%
|
Keros Therapeutics Inc
Glance View
In the heart of the biotechnology sector lies Keros Therapeutics Inc., a company heralded for its innovative approach in addressing unfulfilled needs within hematological and musculoskeletal disorders. Established with a keen focus on advancing therapies derived from the Transforming Growth Factor-Beta (TGF-β) family of proteins, Keros aims to reshape the treatment landscape of complex diseases. Through a scientific approach anchored in proprietary technology, Keros navigates the intricate pathways of cellular growth and differentiation, thereby developing therapeutics with the potential to significantly improve patients' quality of life. Their pipeline, headlined by lead product candidates like KER-050 and KER-047, targets conditions such as myelodysplastic syndromes and fibrodysplasia ossificans progressiva, conditions that have long posed challenges to traditional medical interventions. Keros Therapeutics generates revenue primarily through the development and potential commercialization of its targeted therapies. By advancing their candidates through various clinical trial phases, Keros seeks to unlock significant market opportunities in sectors characterized by high demand and limited treatment options. Partnerships and strategic collaborations further bolster their financial backbone, as these relationships often bring in milestone payments and future royalty arrangements. The company’s model is one of strategic innovation—leveraging cutting-edge science to address critical health issues while carving out a competitive niche in the biotechnology market. This robust approach not only fuels potential breakthroughs but also charts a sustainable path toward profitability in an industry where the aspirations to alleviate complex medical conditions align seamlessly with business growth potentials.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Keros Therapeutics Inc's most recent financial statements, the company has Net Margin of 2%.
You don't have any saved screeners yet